Hormone and nonhormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene

Journal of Women's Health

Volumn 7, Issue 7, 1998, Pages 839-847

  Barrett Connor, Elizabeth ^a   Wenger, Nanette Kass ^b   Grady, Deborah ^c   Mosca, Lori ^d   Collins, Peter ^e   Kornitzer, Marcel ^f   Cox, David A ^g   Moscarelli, Elena ^g   Anderson, Pamela W ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; CHOLESTEROL; ESTROGEN; GESTAGEN; LIPID; RALOXIFENE; TAMOXIFEN; TRIACYLGLYCEROL;

BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; MENOPAUSE; META ANALYSIS; MORTALITY; NONHUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS CANCER;

EID: 0031708649     PISSN: 10597115     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.1998.7.839     Document Type: Review

References (61)

1. Ettinger B. Overview of estrogen replacement therapy: A historical perspective. Proc Soc Exp Biol Med 1998;217:2.
2. Melton LJ III. How many women have osteoporosis now? J Bone Miner Res 1995;10:175.
3. Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763.
4. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1.
5. Wenger NK. Coronary heart disease: An older woman's major health risk. Br Med J 1997;315:1085.
6. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 1995;92:5.
7. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Annu Rev Public Health 1998;19:55.
8. Wenger NK. Postmenopausal hormone therapy: Is it useful for coronary prevention? Cardiol Clin 1998;16:17.
9. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995;87:1067.
10. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA 1998;279:688.
11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,075 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047.
12. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304.
13. Beresford SA, Weiss NS, Voigt LF, McKnight BS. Risk of endometrial cancer in relation to use of oestrogen in combination with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458.
14. Daly E, Vessey MP, Hawkins MW, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348:977.
15. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogen. Lancet 1996;348:981.
16. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983.
17. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605.
18. Petitti DB, Sidney S, Perlman JA. Increased risk of cholecystectomy in users of supplemental estrogen. Gastroenterology 1988;94:91.
19. Vogel RA, Corretti MC. Estrogens, progestins, and heart disease. Can endothelial function divine the benefit? Circulation 1998;97:1223.
20. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199.
21. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389.
22. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clin Trials 1998;19:61.
23. Vickers MR, Meade TW, Wilkes HC. Hormone replacement therapy and cardiovascular disease: The case for a randomized controlled trial. CIBA Found Symp 1995;1991:150.
24. Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley S, for the HERS Research Group. Heart and Estrogen/Progestin Replacement Study (HERS). Controlled Clin Trials 1998;19:314.
25. Barrett-Connor E, Stuenkel C. Anticipating HERS: Questions from the Heart and Estrogen/Progestin Replacement Study. J Women's Health 1998;7:1.
26. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators. Hormone Res 1997;48:155.
27. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326: 852.
28. Grey AB, Stapleton JP, Evans MC, Reid JR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995;80:3191.
29. Mannuci PM, Bettega D, Chantarangkui V, Tripodi A, Sacchini V, Veronisi U. Effect of tamoxifen on measurements of hemostasis in healthy postmenopausal women. Arch Intern Med 1996;156:1806.
30. Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein (a) concentration in healthy postmenopausal women. Arteriosclerosis Thromb 1994;14:1586.
31. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. Br Med J 1995;311:977.
32. Rutvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women in early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85:1389.
33. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997;89:776.
34. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. Br Med J 1991;303:435.
35. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451.
36. Cohen I, Rosen DJD, Shapira J, et al. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993; 100:567.
37. Malfetano JH. Tamoxifen: Associated endometrial carcinoma in postmenopausal breast and endometrial cancer. Gynecol Oncol 1990;39,82.
38. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63.
39. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905.
40. Sato M, Bryant HU, Iversen P, et al. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J Pharmacol Exp Ther 1996;279:298.
41. Kauffman RF, Bensch WR, Roudebush RE, et al. Hypocholesterolemic activity of raloxifene (LY139481): Pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther 1997; 280:146.
42. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997;96:1964.
43. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis in postmenopausal monkeys. J Clin Endocrinol Metab, 1998;83:721.
44. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCl). Atherosclerosis 1996; 126:65.
45. Rahimian R, Laher I, Dube G, van Breemen C. Estrogen and selective estrogen receptor modulator LY117018 enhance release of nitric oxide in rat aorta. J Pharmacol Exp Ther 1997;283:116.
46. Wiernicki T, Glasebrook A, Phillips DL, Singh J. Estrogen and a novel tissue selective estrogen receptor modulator raloxifene directly modulate vascular smooth muscle cell functions: Implications in the cardioprotective mechanism of estrogen. Circulation 1996;94(Suppl 1):I278.
47. Walsh BW, Kuller LH, Wild RA, et al. The effect of raloxifene on markers of cardiovascular risk in healthy, post-menopausal women. JAMA 1998;279, 1445.
48. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy, postmenopausal women. J Bone Miner Res 1996;11:835.
49. Delmas P, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641.
50. Miller NE. Associations of high density lipoprotein subclasses with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987;113:589.
51. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary artery disease and mortality in middle-aged men and women. Eur Heart J 1998;19:55.
52. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001.
53. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1459.
54. Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter, double-blind, randomized trials in ≃12,000 postmenopausal women. Proc Am Soc Clin Oncol 1998;17:122a (abstract).
55. Cummings SR, Norton L, Eckert S, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Proc Am Soc Clin Oncol 1998;17:2a (abstract).
56. Grady D, Rubin SM, Pettiti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016.
57. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987;106:40.
58. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy. Effect on bone, plasma estra-diol concentrations, endometrium, and lipid levels. Arch Intern Med 1997;157:2609.
59. Evista [package insert]. Indianapolis, IN: Eli Lilly and Company, 1998.
60. World Health Organization. Research on the menopause in the 1990's. WHO Technical Report Series 866. Geneva: WHO, 1996.
61. Glusman J, Lu Y, Huster W, Eckert S, Davies G, Lakshmanan M. Raloxifene effects on climacteric symptoms compared with hormone or estrogen replacement therapy (HRT or ERT). [abstract]. In: The North American Menopause Society 8th Annual Meeting Program. Boston, September 4-6, 1997, p 65 (Abstract nr 97.040 P26).